1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow B: FMXIN002 3.6mg: new trials by email Literature Review of B: FMXIN002 3.6mg trials Research Report on B: FMXIN002 3.6mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Bioavailability of Intranasal Epinephrine A: Epinephrine injection, B: FMXIN002 3.6mg, C: FMXIN002 4.0mg - Anaphylaxis, Anaphylactic Reaction | Phase 1 / Phase 2 | Completed | Nasus Pharma | 12 | 2023-08-22 | 2025-06-18 |
Anaphylaxis (1)
Nasus Pharma (1)
Israel (1)